Lori A Hazlehurst
Overview
Explore the profile of Lori A Hazlehurst including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1364
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yi W, Dziadowicz S, Mangano R, Wang L, McBee J, Frisch S, et al.
Int J Mol Sci
. 2024 Aug;
25(16).
PMID: 39201707
Multiple myeloma is the second most hematological cancer. RUVBL1 and RUVBL2 form a subcomplex of many chromatin remodeling complexes implicated in cancer progression. As an inhibitor specific to the RUVBL1/2...
2.
Wang L, Yi W, Ma L, Lecea E, Hazlehurst L, Adjeroh D, et al.
Cancers (Basel)
. 2023 Nov;
15(21).
PMID: 37958322
Bone marrow mesenchymal stem cells (BM MSCs) play a tumor-supportive role in promoting drug resistance and disease relapse in multiple myeloma (MM). Recent studies have discovered a sub-population of MSCs,...
3.
Newton E, Starcovic S, Menze M, Konkle M, Long T, Hazlehurst L, et al.
Bioorg Med Chem Lett
. 2023 May;
89:129310.
PMID: 37137430
MitoNEET belongs to the CDGSH Iron-Sulfur Domain (CISD)-gene family of proteins and is a [2Fe-2S] cluster-containing protein found on the outer membrane of mitochondria. The specific functions of mitoNEET/CISD1 remain...
4.
Ivey A, Fagan B, Murthy P, Lotze M, Zeh H, Hazlehurst L, et al.
Clin Exp Immunol
. 2023 Jan;
211(3):239-247.
PMID: 36655514
Neutrophil extracellular traps (NETs) occur when chromatin is decondensed and extruded from the cell, generating a web-like structure. NETs have been implicated in the pathogenesis of several sterile disease states...
5.
Johnson B, Kaulagari S, Chen W, Hayes K, Geldenhuys W, Hazlehurst L
ACS Bio Med Chem Au
. 2022 Jul;
2(2):161-170.
PMID: 35892127
The flavin adenine dinucleotide containing Endoplasmic Reticulum Oxidoreductase-1 α (ERO1α) catalyzes the formation of disulfide bond formation of secretory and transmembrane proteins and contributes towards proper protein folding. Recently, increased...
6.
Jain P, Badger D, Liang Y, Gebhard A, Santiago D, Murray P, et al.
Pept Sci (Hoboken)
. 2022 Jul;
113(3):e24199.
PMID: 35859761
HYD1 is an all D-amino acid linear 10-mer peptide that was discovered by one-bead-one-compound screening. HYD1 has five hydrophobic amino acids flanked by polar amino acids. Alanine scanning studies showed...
7.
Jones C, Dziadowicz S, Suite S, Eby A, Chen W, Hu G, et al.
Cancers (Basel)
. 2022 Jul;
14(13).
PMID: 35804837
MTI-101 is a first-in-class cyclic peptide that kills cells via calcium overload in a caspase-independent manner. Understanding biomarkers of response is critical for positioning a novel therapeutic toward clinical development....
8.
Dziadowicz S, Wang L, Akhter H, Aesoph D, Sharma T, Adjeroh D, et al.
Cancers (Basel)
. 2022 Feb;
14(4).
PMID: 35205675
Multiple myeloma (MM) is a hematological cancer with inevitable drug resistance. MM cells interacting with bone marrow stromal cells (BMSCs) undergo substantial changes in the transcriptome and develop de novo...
9.
Jones C, Hazlehurst L
Biomedicines
. 2021 Sep;
9(9).
PMID: 34572386
Calcium is essential for cells to perform numerous physiological processes. In cancer, the augmentation of calcium signaling supports the more proliferative and migratory cells, which is a characteristic of the...
10.
Elzamzamy O, Johnson B, Chen W, Hu G, Penner R, Hazlehurst L
Cells
. 2021 Jul;
10(6).
PMID: 34199280
Multiple myeloma (MM) is a currently incurable hematologic cancer. Patients that initially respond to therapeutic intervention eventually relapse with drug resistant disease. Thus, novel treatment strategies are critically needed to...